Get the Stockscreener App
0.06
0.00%
0.00
Nkgen Biotech Inc stock is traded at $0.06, with a volume of 510.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
See More
Previous Close:
$0.06
Open:
$0.06
24h Volume:
510
Relative Volume:
0.06
Market Cap:
$N/A
Revenue:
$3,000
Net Income/Loss:
$-23.55M
P/E Ratio:
-0.0492
EPS:
-1.2183
Net Cash Flow:
$-19.75M
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
-54.72%
1Y Performance:
-92.59%
1-Day Range:
$0.06
$0.06
1-Week Range:
$0.06
$0.06
52-Week Range:
$0.0003
$0.345
Nkgen Biotech Inc Stock (NKGN) Company Profile
Compare NKGN vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.06 | 0 | 3,000 | -23.55M | -19.75M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Nkgen Biotech Inc Stock (NKGN) Latest News
NKGen reports cognitive stability in moderate Alzheimer’s trial By Investing.com - Investing.com Australia
NKGen reports cognitive stability in moderate Alzheimer’s trial - Investing.com
As of January 31, 2026, the latest financial data disclosed by Western Asset Municipal High Income Fund Inc shows that its total net asset value has reached 154.63 millions USD. - Bitget
NKGen Biotech Inc. (hereinafter referred to as NKGen Biotech) announced the integrated Phase 1 clinical trial data for its candidate therapy Troculeucel at the Ad/Pd 2026™ conference. - Bitget
NKGen Biotech Reports Combined Phase 1 Troculeucel Data - GlobeNewswire
NKGen Biotech Korea Co., Ltd.: Dividend historical data and projections - marketscreener.com
Troculeucel may boost cognition, new Alzheimer’s data shows - Longevity.Technology
NKGen to present Alzheimer’s therapy data at AD/PD conference - Investing.com India
NKGen to present Alzheimer’s therapy data at AD/PD conference By Investing.com - Investing.com Canada
NKGen Biotech to Present Integrated Phase 1 Clinical and - GlobeNewswire
Net income of NKGen Biotech Inc. – OTC:NKGNW - TradingView
NKGen Biotech Secures Additional Debt Financing from AlpineBrook - TipRanks
Nkgen Biotech amends loan agreement to secure additional $343,000 funding - Investing.com
NKGen Biotech Adds $343,000 via Fourth Amendment to AlpineBrook Secured Note; Principal Now $27.1M - TradingView
NKGen Biotech (NKGN) adds $343,000 under AlpineBrook note - Stock Titan
NKGen Biotech, Inc. and NKGen Operating Biotech, Inc. Enter Amendment to Secured Promissory Note Increases Loan Principal and Funding - marketscreener.com
NKGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NKGNNKGen Biotech Inc Latest Stock News & Market Updates - Stock Titan
NKGen Biotech increases loan principal by $251,000 under amended agreement By Investing.com - Investing.com Nigeria
NKGen Biotech increases loan principal by $251,000 under amended agreement - Investing.com South Africa
NKGen Biotech expands debt financing with loan amendment - TipRanks
NKGen Biotech Signs Amendment to Secured Promissory Note With AlpineBrook Capital - TradingView
Pre-Market Top Gainer: NKGNW NKGen Warrants NASDAQ $0.0301 Feb 2026: key setup - Meyka
Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ) - Defense World
NKGen Biotech amends loan agreement and extends forward purchase deal By Investing.com - Investing.com Nigeria
NKGen Biotech amends loan agreement and extends forward purchase deal - Investing.com
NKGen Biotech Signs Multiple Financing Agreements - TradingView
NKGen Biotech Secures Additional Funding via Note Amendment - TipRanks
NKGen Biotech confirms successful acquisition of NKMax - intellectia.ai
NKGen Biotech Appoints Bruce Miller to Scientific Advisory Board - Intellectia AI
NKGen Biotech appoints neurology expert Dr. Bruce Miller to advisory board - Investing.com Nigeria
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board - The Globe and Mail
NKGen Biotech, Inc. SEC 10-Q Report - TradingView — Track All Markets
Nkgen Biotech amends loan agreement to secure additional $295,000 funding - Investing.com India
Nkgen Biotech amends loan agreement to secure additional $295,000 funding By Investing.com - Investing.com South Africa
NKGen Biotech Expands Debt Financing Through Note Amendment - TipRanks
NKGen Biotech Signs Amendment to Secured Promissory Note With AlpineBrook Capital GP I - TradingView — Track All Markets
NKGen Biotech, Inc. and NKGen Operating Biotech, Inc., Enter into an Amendment to Certain Secured Promissory Note with AlpineBrook Capital GP I Limited - marketscreener.com
NKGen Biotech enters $25.8 million secured note agreement with AlpineBrook Capital - Investing.com Australia
NKGen Biotech enters $25.8 million secured note agreement with AlpineBrook Capital By Investing.com - Investing.com South Africa
NKGen Biotech Secures New Promissory Note Financing - TipRanks
NKGen Biotech Signs Secured Promissory Note With AlpineBrook Capital GP I - TradingView
Nkgen Biotech Inc Stock (NKGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Cap:
|
Volume (24h):